Abstract | AIMS: Low 25-hydroxy-vitamin D [25(ΟΗ)D] levels have been associated with increased risk for cardiovascular disease. Conflicting data exist regarding the effect of statins on [25( OH)D] levels. The aim of this study was to compare the effect of atorvastatin and rosuvastatin on 25( OH)D levels in non-diabetic patients with dyslipidaemia. METHODS: This was a prospective randomized open-label study. Patients were assigned to atorvastatin 20 mg⁄day (n=28, age: 56.1±2.2 years, 22 females) or rosuvastatin 10 mg⁄day (n=24, age: 57.4±1.9 years, 20 females). Total cholesterol (TC), low- ( LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting plasma glucose, insulin, glycosylated haemoglobin A1c (HbA1c) and high sensitivity C-reactive protein ( hsCRP) levels were measured, and homeostatic model of assessment insulin resistance (HOMA-IR) was calculated at baseline and 12 weeks post-treatment. RESULTS: There were no within or between group significant differences in 25( OH)D levels ( atorvastatin: 21.7±1.9 ng/ml at baseline and 23.5±2.3 ng/ml at week 12; rosuvastatin: 25.3±1.8 and 27.0±2.4 ng/ml, respectively; p=0.172 and p=0.306 for between groups, respectively). Both statins significantly reduced TC, TG and LDL-C levels, with a greater LDL-C reduction being observed by rosuvastatin. CONCLUSION:
|
Authors | Panagiotis Anagnostis, Fotini Adamidou, Aristidis Slavakis, Stergios A Polyzos, Despina Selalmatzidou, Athanasios Panagiotou, Vasilios G Athyros, Asterios Karagiannis, Marina Kita |
Journal | The open cardiovascular medicine journal
(Open Cardiovasc Med J)
Vol. 8
Pg. 55-60
( 2014)
ISSN: 1874-1924 [Print] United Arab Emirates |
PMID | 25110531
(Publication Type: Journal Article)
|